Spinal Metastases Due to Thyroid Carcinoma

Kushchayeva, Yevgeniya S.; Kushchayev, Sergiy V.; Carroll, Nancy M.; Felger, Erin A.; Links, Thera; Teytelboym, Oleg M.; Bonichon, Francoise; Preul, Mark C.; Sonntag, Volker K. H.; Van Nostrand, Douglas

Published in:
Thyroid

DOI:
10.1089/thy.2013.0633

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2014

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 16-11-2018
Spinal Metastases Due to Thyroid Carcinoma: An Analysis of 202 Patients

Yevgeniya S. Kushchayeva,1,2 Sergiy V. Kushchayev,3,4 Nancy M. Carroll,2 Erin A. Felger,2 Thera P. Links,5 Oleg M. Teytelboym,3 Françoise Bonichon,6 Mark C. Preul,4 Volker K.H. Sonntag,4 Douglas Van Nostrand,7 Kenneth D. Burman,8 and Lisa M. Boyle9

Background: Spinal metastases (SMs) due to thyroid cancer (TC) are associated with significantly reduced quality of life. The goal of this study is to analyze the clinical manifestations, presentation, and treatments of TC SMs, and to describe specific features of SMs associated with different TC types.

Patients and Methods: A retrospective analysis of 202 TC SM patients treated at Medstar Washington Hospital Center (37) and collected from the literature (165) was performed.

Results: The mean age of patients with SMs was 56.9 ± 14.7 years, and the female-to-male ratio was 2.1:1. Of all patients, 29% (28% of follicular thyroid cancer [FTC] and 37% of papillary thyroid cancer [PTC]) had SMs only. Twenty-nine percent of all patients and 54% of patients with single-site SMs had neither bone non-SMs nor solid organ metastases at the time of presentation. Thirty-five percent of patients had SMs as an initial presentation of TC. TC patients presenting with SMs had a lower rate of other bone and visceral involvement compared with patients whose SMs were diagnosed at the time of thyroid surgery or during follow-up (p < 0.05). SMs were more often the initial manifestation of FTC (41% vs. 24%), while PTC SMs were more commonly diagnosed after TC diagnosis (76% vs. 59%; p < 0.05). PTC SMs were more frequently diagnosed as synchronous (63% vs. 36% in FTC) versus FTC SMs that developed as metachronous metastases (64% vs. 37% in PTC; p < 0.01). All FTC SMs developed within 82 (0–372) months and all PTC SMs within 35 (0–144) months (p < 0.01). In FTC SMs as TC manifestation, solid organ metastases involvement was less common than in FTC SMs that were found after TC diagnosis (34% vs. 67%; p < 0.01); multisite FTC SMs compared to solitary FTC SMs were associated with the development of other bone nonskeletal metastases (82% vs. 30%; p < 0.01) and solitary organ metastases (65% vs. 41%; p < 0.01). These correlations were not observed in PTC SMs. FTC patients often had neural structure compression (myelopathy/radiculopathy; 72% vs. 36% in PTC), while PTC patients frequently were asymptomatic (38% vs. 5% in FTC; p < 0.01). FTC SMs more commonly were 131I-avid (p < 0.01). FTC patients required surgery more frequently (72% vs. 55% in PTC; p < 0.05).

Conclusions: Our study reveals that a significant part of TC SMs patients have solitary spinal involvement at the time of presentation and may be considered for aggressive treatment with the intention to improve quality of life and survival. FTC SMs and PTC SMs appear to have distinct presentations, behavior, and treatment modalities, and should be categorized separately for treatment and follow-up planning.

Introduction

In most instances, thyroid carcinoma (TC) presents as an indolent tumor and is usually associated with relatively favorable long-term survival (1). However, when distant metastases occur, the overall survival rate is only 40% after 10 years (1,2). Distant metastases are the most frequent cause of TC-related death (2,3).

Spinal metastases (SM) are the most common site of TC bone metastases, developing in more than 3% of patients with

Departments of 1Internal Medicine and Surgery, 2General Surgery, 7Nuclear Medicine, 8Endocrinology, and 9Surgery, Medstar Washington Hospital Center, Washington, District of Columbia.

3Department of Radiology, Mercy Fitzgerald Hospital, Darby, Pennsylvania.

4Division of Neurological Surgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, Arizona.

5Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

6Department of Nuclear Medicine, Bergonié Institute, Bordeaux, France.
Materials and Methods

We reviewed the Medstar WHC database and identified 37 patients with TC SMs. This study was approved by the Medstar WHC Institutional Review Board. We searched the following databases for studies on TC and SMs using all relevant keyword variations: PubMed, Cochrane Library, Web of Science, Google Scholar, and Science Direct. A total of 56 studies published from 1981 to 2012 were located and systematically analyzed (2,7–61). Research completed more than 20 years ago was excluded from our study because the methods used at that time for diagnosis and treatment differ from the current approaches, for example computed tomography (CT) was not used for SMs in those days. As a result, data from 202 patients with SMs were collected and analyzed in the present study. Previously published patient data from the University of Groningen (Groningen, The Netherlands) and the Bergonie Institute (Bordeaux, France) published previously were updated, and important information was added for analysis by this study’s co-authors (TL and FB).

An analysis of the literature identified two patterns of SMs: the initial presentation of TC as SMs (Group S; “spinal manifestation”), and SMs that were identified at the time or developed after TC diagnosis (Group T; “thyroid manifestation” of TC). According to the time interval from TC diagnosis to the detection of SMs, metastases were classified into two types: synchronous and metachronous. Synchronous metastases were identified as metastases that were apparent at the time of TC presentation or within six months following diagnosis, while metachronous metastases were defined as metastases that had developed more than six months after TC diagnosis.

Because selected manuscripts were published from various clinical departments and different aspects of the SMs were described with missing data and follow-up information, all analyses and calculations of particular characteristics were performed depending on the availability of details about the patients. Chi-square methods, the dispersing method (F), and the Student’s method (t-test) were used for the statistical analysis of the cancer-related variables.

Results

General characteristics of thyroid cancer spinal metastases

Demography. Among the 202 patients selected for the study, 41% were males and 59% were female. The patients’ mean age at the time of TC presentation was 56.9 ± 14.7 years. In terms of the primary histological classification, 63% of the patients presented with follicular TC (FTC), 28% with papillary TC (PTC), 5% with medullary TC (MTC), 3% with Hürthle cell carcinoma (HCC), and 1% with anaplastic TC (ATC; Fig. 1). The status of the distant metastases other than SMs was available in for 142 patients: 37% had both bone non-SMs and solid organ metastases, 22% had other bone non-SMs, 12% had solid organ metastases, and 29% had neither bone non-SMs nor solid organ metastases. Single-site SMs were found in 49% of the patients, and 51% of the patients had multisite involvement (two or more vertebral involved). Importantly, 54% of all the TC patients with single-site SMs did not have any other distant metastases. A summary of the patients’ demographics, clinical features, histology, and treatments modalities is shown in Table 1. The mean follow-up was 42 months (0–191 months).

Clinical presentation. The initial presentation of TC as SMs (Group S) was found in 35% of the patients. SMs that were identified at the time of the initial diagnosis of TC or that developed after TC diagnosis (Group T) were evident in 65% of the patients (Fig. 2).

TC with spinal manifestations (Group S). Vertebral involvement can occur due to the direct spreading of TC (direct

FIG. 1. The primary histological classification of thyroid spinal metastases. One hundred and twenty (63%) patients had FTC, 54 (28%) had PTC, 9 (5%) with MTC, 6 (3%) had HCC, and 2 (1%) had ATC (11 patients had tumor of unknown histology).
involvement) with a subsequent extension into the spinal canal, or as the indirect (hematogeneous/lymphogeneous) spreading of malignant cells. All three cases of direct spread of TC into the spinal canal occurred in patients with PTC. All had spinal cord compression and died soon after their neurological symptoms manifested.

TC with thyroid manifestations (Group T). Synchronous metastases were found in 46% of patients in Group T (30% of all TC patients), and metachronous metastases were diagnosed in 54% of patients in Group T (35% of all TC patients). When Group S, Group T synchronous SMs, and Group T metachronous SMs were compared, bone non-SMs and solid organ metastases were less common in Group S and more prevalent in Group T metachronous SMs ($p < 0.05$; Fig. 2).

Diagnosis of SMs. As many as 57% of the patients presented with symptoms of neuronal structure compression, including spinal cord compression (myelopathy with or without root compression) in 45% and root compression (radiculopathy) in only 12% of patients. Back pain was found to be an initial symptom in 28% of patients. The remaining 15% of patients were asymptomatic, and their metastases were found during routine evaluation at the time of the initial diagnosis or at the subsequent follow-up.

Treatment of the primary TC. Of 151 patients, 131 (87%) underwent a total thyroidectomy upon TC diagnosis. Eleven

### Table 1. Demographics, Clinical, Pathological Stage, and Treatment Characteristics of Patients with Thyroid Cancer

<table>
<thead>
<tr>
<th></th>
<th>All TC (n = 202)</th>
<th>FTC (n = 120)</th>
<th>PTC (n = 54)</th>
<th>MTC (n = 9)</th>
<th>HCC (n = 6)</th>
<th>ATC (n = 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>81 (41%)</td>
<td>41 (34%)</td>
<td>29 (55%)</td>
<td>3 (33%)</td>
<td>3 (50%)</td>
<td>2 (100%)</td>
</tr>
<tr>
<td>Females</td>
<td>118 (59%)</td>
<td>79 (66%)</td>
<td>24 (45%)</td>
<td>6 (67%)</td>
<td>3 (50%)</td>
<td>0</td>
</tr>
<tr>
<td>Female:Male ratio</td>
<td>2:1:1</td>
<td>1:9:1</td>
<td>0.8:1</td>
<td>3:1</td>
<td>1:1</td>
<td>0:2</td>
</tr>
<tr>
<td>Mean age, years</td>
<td>56.9 ± 14.7</td>
<td>56.7 ± 14.4</td>
<td>57.8 ± 13.9</td>
<td>49.3 ± 15</td>
<td>64.7 ± 5.7</td>
<td>60 ± 21</td>
</tr>
<tr>
<td><strong>Vertebral lesions:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean vertebral lesions per patient</td>
<td>1.91</td>
<td>1.94</td>
<td>1.91</td>
<td>3.2</td>
<td>1.5</td>
<td>3.0</td>
</tr>
<tr>
<td>Solitary spinal metastases</td>
<td>95 (49%)</td>
<td>46 (47%)</td>
<td>24 (46%)</td>
<td>2 (28%)</td>
<td>3 (50%)</td>
<td>0</td>
</tr>
<tr>
<td>Multiple spinal metastases</td>
<td>99 (51%)</td>
<td>60 (53%)</td>
<td>28 (54%)</td>
<td>5 (72%)</td>
<td>3 (50%)</td>
<td>2 (100%)</td>
</tr>
<tr>
<td><strong>Metastases:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal metastases only</td>
<td>41 (29%)</td>
<td>24 (28%)</td>
<td>16 (37%)</td>
<td>1 (14%)</td>
<td>1 (25%)</td>
<td>0</td>
</tr>
<tr>
<td>Spinal metastases and bone nonspecific metastases</td>
<td>31 (22%)</td>
<td>21 (24%)</td>
<td>9 (21%)</td>
<td>0</td>
<td>1 (25%)</td>
<td>0</td>
</tr>
<tr>
<td>Spinal metastases and solid organ metastases</td>
<td>17 (12%)</td>
<td>12 (14%)</td>
<td>5 (12%)</td>
<td>0</td>
<td>1 (25%)</td>
<td>0</td>
</tr>
<tr>
<td>Spinal metastases, bone nonspecific metastases, and solid organ metastases</td>
<td>53 (37%)</td>
<td>29 (34%)</td>
<td>13 (30%)</td>
<td>6 (86%)</td>
<td>1 (25%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td><strong>Group S</strong> (Spinal metastases as a manifestation of thyroid cancer)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal metastases only</td>
<td>41 (29%)</td>
<td>24 (28%)</td>
<td>16 (37%)</td>
<td>1 (14%)</td>
<td>1 (25%)</td>
<td>0</td>
</tr>
<tr>
<td>Spinal metastases and bone nonspecific metastases</td>
<td>31 (22%)</td>
<td>21 (24%)</td>
<td>9 (21%)</td>
<td>0</td>
<td>1 (25%)</td>
<td>0</td>
</tr>
<tr>
<td>Spinal metastases and solid organ metastases</td>
<td>17 (12%)</td>
<td>12 (14%)</td>
<td>5 (12%)</td>
<td>0</td>
<td>1 (25%)</td>
<td>0</td>
</tr>
<tr>
<td>Spinal metastases, bone nonspecific metastases, and solid organ metastases</td>
<td>53 (37%)</td>
<td>29 (34%)</td>
<td>13 (30%)</td>
<td>6 (86%)</td>
<td>1 (25%)</td>
<td>1 (100%)</td>
</tr>
<tr>
<td><strong>Group T</strong> (Spinal metastases developed at the time of thyroid cancer diagnosis or during follow-up)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group T—synchronous metastases</td>
<td>42 (46%)</td>
<td>17 (36%)</td>
<td>20 (63%)</td>
<td>1 (25%)</td>
<td>1 (25%)</td>
<td>2 (100%)</td>
</tr>
<tr>
<td>Group T—metachronous metastases</td>
<td>50 (54%)</td>
<td>30 (64%)</td>
<td>12 (37%)</td>
<td>3 (75%)</td>
<td>3 (75%)</td>
<td>0</td>
</tr>
<tr>
<td>Mean time between thyroid cancer and spinal metastases developing (Group T), months</td>
<td>128</td>
<td>34</td>
<td>152</td>
<td>98</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td><strong>Order of distant metastases appearance:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial bone metastases</td>
<td>77 (72%)</td>
<td>52 (81%)</td>
<td>23 (64%)</td>
<td>0</td>
<td>2 (50%)</td>
<td>NA</td>
</tr>
<tr>
<td>Initial solid organ metastases</td>
<td>5 (5%)</td>
<td>3 (5%)</td>
<td>2 (5%)</td>
<td>0</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Initial bone metastases and solid organ metastases</td>
<td>24 (23%)</td>
<td>9 (14%)</td>
<td>11 (31%)</td>
<td>1 (100%)</td>
<td>2 (50%)</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Clinical presentation:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myelopathy</td>
<td>67 (45%)</td>
<td>51 (57%)</td>
<td>13 (28%)</td>
<td>1 (20%)</td>
<td>2 (33%)</td>
<td>NA</td>
</tr>
<tr>
<td>Radiculopathy</td>
<td>18 (12%)</td>
<td>13 (15%)</td>
<td>4 (9%)</td>
<td>0</td>
<td>1 (17%)</td>
<td>NA</td>
</tr>
<tr>
<td>Back pain</td>
<td>42 (28%)</td>
<td>21 (23%)</td>
<td>12 (25%)</td>
<td>4 (80%)</td>
<td>2 (33%)</td>
<td>NA</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>23 (15%)</td>
<td>4 (5%)</td>
<td>18 (38%)</td>
<td>0</td>
<td>1 (17%)</td>
<td>NA</td>
</tr>
<tr>
<td><strong>SMs treatments:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>122 (67%)</td>
<td>83 (72%)</td>
<td>26 (55%)</td>
<td>4 (50%)</td>
<td>2 (33%)</td>
<td>1 (50%)</td>
</tr>
<tr>
<td>Conservative treatment</td>
<td>45 (24%)</td>
<td>21 (18%)</td>
<td>13 (28%)</td>
<td>4 (50%)</td>
<td>4 (67%)</td>
<td>1 (50%)</td>
</tr>
<tr>
<td>Radiosurgery</td>
<td>7 (4%)</td>
<td>2 (2%)</td>
<td>5 (11%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>No treatment</td>
<td>9 (5%)</td>
<td>6 (5%)</td>
<td>3 (6%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
(7%) patients initially underwent a hemithyroidectomy for a “benign thyroid tumor” and later underwent total thyroidectomy upon being diagnosed with TC due to the manifestation of SMs. Nine (6%) patients with SMs did not receive any thyroid surgery due to, for example, patient refusal or high operative risk. $^{131}$I ablation was performed in 94% of the patients with differentiated TC.

Treatment of the SMs. Information about the treatment for SMs in 183 of the TC patients was available for analysis. Of those, 67% received surgery, 24% nonsurgical treatment, 4% radiosurgery, and 5% of the patients did not undergo any of these therapies. Radical surgical treatment, that is, total removal of the metastatic lesions in the patients with single isolated SMs, was performed in 16 (13%) of the patients. Embolization was used in 72 cases (39%), with preoperative embolization before radical or palliative surgery in 55 (76%) of those patients. It was the only treatment in 17 (24%) patients. Radiotherapy was the leading treatment for the patients who received nonsurgical therapy; it was applied in 39 (87%) of 45 patients. Of the surgical patients, 48 (39%) also received external radiation.

**Tumor type-specific data**

**FTC.** Among the 120 patients with FTC, 66% were females and 34% were males. Their mean age was $56.7 \pm 14.4$ years. Of those patients, 48% had solitary SMs and 52% multiple SMs. The distribution of the metastatic lesions followed the localization of the radiculomedullary arteries that supply the spinal cord (Fig. 3A and B). Patients with both bone non-SMs and solid organ metastases, as well as patients with bone non-SMs, were more common among the multisite SMs group. The patients who did not have solid organ metastases and bone non-SMs were more prevalent in the solitary SM group ($p<0.01$). Thus, multiple SMs of the FTC

![FIG. 2. Schematic illustration of the presentation of spinal metastases secondary to thyroid carcinoma. In our study, about 35% of spinal metastases presented as an initial manifestation of thyroid cancer; 30% of the patients had synchronous metastases, and 35% had metachronous metastases. Follicular thyroid cancer was found to be more common in spinal metastases that manifested thyroid carcinoma, and as metachronous metastases, while papillary thyroid carcinoma was prevalent in synchronous metastases ($p<0.05$). Spinal metastases that manifested thyroid carcinoma had the highest incidence of solitary lesions (49%), while metachronous metastases had the lowest prevalence at 38%. Patients with spinal metastases that manifested thyroid carcinoma as compared with patients whose spinal metastases were diagnosed at the time of thyroid surgery or during follow-up had the lowest level of solid organ metastases (35.8%) and the highest level of isolated spinal metastases (38%), and 26.2% of the patients had spinal metastases and other bone nonspine metastases. In total, 50% of the patients with metachronous spinal metastases had accompanying solitary organ metastases; 25% had concomitant bone nonspine metastases, and only 25% of the patients with spinal metastases had no other distant metastases. The majority of the patients (80%) with metachronous spinal metastases had solitary organ metastases, only 10% of the patients had spinal metastases and other bone nonspine metastases, and 10% of the patients had isolated spinal metastases ($p<0.05$).](image-url)
FIG. 3. Distribution of spinal metastases originated from follicular and papillary thyroid carcinomas. (A) Our analysis revealed that the distribution of spinal metastases secondary to follicular thyroid carcinoma matches the localization of the medullary segmental arteries: the number of involved vertebrae was highest at the levels of medullary segmental artery localization and lowest at the watershed areas. The distribution of spinal metastases secondary to papillary cancer does not match the localization of the medullary segmental arteries. (B) A possible explanation of the phenomenon in Figure 3A. Follicular thyroid carcinoma has a tendency to spread hematogenously. Segmental radicular arteries enter the intervertebral foramina and travel along the nerve roots. Selected anterior radicular arteries form anterior radiculomedullary branches, providing a segmental arterial supply to the spinal cord: the large cervical radiculomedullary artery occurs at level C5–C7; the upper thoracic segment is generally perfused by a single dominant radiculomedullary artery arising from T4–T5; the artery of Adamkiewicz is the largest radiculomedullary artery and is most commonly located at T10 on the left side; the additional radiculomedullary artery of Deproges–Gotteron arises at the L4–L5 level. The segmental arteries (A) divide into numerous branches at the intervertebral foramen, supplying the bone structures. The segmental arteries that give rise to the radiculomedullary arteries (B) and (C) are supposed to be larger than the other segmental arteries, and thus blood flow in these vessels and in their vertebral body branches (D) is higher. The probability of carrying follicular thyroid carcinoma metastases to the vertebral body is therefore high.
were associated with significant metastatic involvement of the solid organs and bones. The FTC Group S comprised 41% of the patients, and 59% of the patients were included in the FTC Group T (Fig. 4). The mean follow-up in this group was 50 months (0–191 months); 59 months for the patients with solitary SMs and 47 months for the patients with multiple PTC SMs.

FTC Group S. None of the FTC patients presented with direct expansion of their tumors to the spine. However, 49% of the patients had solitary SMs and 51% multiple lesions. Bone non-SMs were more common ($p<0.05$) in patients with multisite SMs compared to solitary SMs. There was a trend ($p=0.67$) for multisite SMs to be associated with solid organ metastases. Importantly, 68% of the patients with single-site SM in the FTC Group S did not have any other distant metastases.

FTC Group T. In Group T, 36% of the patients had synchronous metastases, and 64% of the patients developed metachronous metastases within 127.8–94.6 months (12–372 months) after TC was diagnosed. Solitary SMs were found in 47% of the patients, and 53% of the patients had multiple SMs. Patients with multiple SMs had a significantly higher risk of developing both bone non-SMs ($p<0.01$) and solid organ metastases ($p<0.01$). Of the patients with single-site SM in the FTC Group T, 38% did not have any other distant metastases.

FTC Group S versus FTC Group T. When we compared the FTC Group S with the FTC Group T, solid organ metastases were found to be more common in the latter ($p<0.01$). The development of bone non-SMs was not significantly different between the groups.

Appearance of distant FTC metastases. Among the 64 patients available for analysis, 52 (81%) patients had the first distant metastasis localized in the bones (including the spine). In nine (14%) patients, bone and solid organ metastases developed at the same time, and in three (5%) patients, distant metastases manifested with solid organ metastases. This means that, altogether, solid organ metastases were diagnosed as the first distant metastases in 19% of the patients, while 95% of the patients had bone metastases (Fig. 5).

**FIG. 4.** Spinal metastases from follicular thyroid carcinoma. The initial presentation of follicular thyroid carcinoma as spinal metastases (Group S) was found in 45% of all the patients in our study. In this group, 49% of the patients had single-site spinal metastases, and 51% had multiple spinal metastases; a total of 29% of the patients had solid organ metastases, 29% had only bone nonspinal metastases, and 42% had neither bone nonspinal metastases nor solid organ metastases. Spinal metastases that were identified at the time or developed after TC diagnosis (Group T) comprised 55% of all the patients with follicular thyroid cancer. In this group, synchronous metastases were found in 36% of the patients: 53% of them had multiple spinal involvement, 50% had solid organ metastases, 30% had only bone nonspinal metastases, and 20% had neither bone nonspinal metastases nor solid organ metastases. Metachronous metastases were found in 64% of the patients in Group T. The majority of the patients (63%) had multilevel spinal involvement: 82% had solid organ metastases, only 9% had bone nonspinal metastases, and 9% had neither bone nonspinal metastases nor solid organ metastases.
Our analysis revealed a group of patients who had undergone a hemithyroidectomy for a putative thyroid tumor but had developed SMs years later. It is speculated that those patients had minimally invasive FTC that was not diagnosed at the time of surgery. This group consisted of 10 patients, all of whom were females. They had a mean age of 36.4 ± 0.4 years, which meant that they were younger than all the other FTC patients (\( p < 0.001 \)). These metastases also developed later (221.7 ± 138 months) than the other FTC metachronous metastases (101.5 ± 68.4 months; \( p < 0.001 \)). Upon diagnosis of SMs, all the patients underwent total thyroidectomies and radioiodine therapy.

Clinical presentation and treatment. The majority of the patients (72%) presented with symptoms of neuronal structure compression: either myelopathy (57%) or radiculopathy...
Back pain was the initial symptom in 23% of the patients. Only 5% of the patients were asymptomatic. In 66%, the SMs lesions were $^{131}$I avid, while in 34%, they were not. Surgery was performed for 72% of the patients, and nonsurgical treatments were provided for 18%. Radiosurgery was used for 2% of the patients, and 5% received no treatment.

**PTC**

Of the 54 patients with PTC, 55% were male and 45% female. The mean age was 57.8 ± 13.9 years with a trend showing the males to be older than the females (61 ± 10.0 years vs. 54.5 ± 17 years respectively; $p = 0.066$). Within the PTC group, 46% of the patients had solitary SMs with 54% having multiple SMs. All the PTC patients with solitary SMs were significantly older than those with multiple lesions (64 ± 11.7 years vs. 51.4 ± 14 years respectively; $p < 0.001$). Among the patients with PTC solitary SMs, 53% did not have any other metastases. Only 24% of the PTC patients had SMs on presentation of TC (the PTC Group S), while the other 76% were found to have SMs at the time of TC diagnosis or after TC was diagnosed (the PTC Group T; Fig. 6). The mean follow-up for the PTC patients was 38 months (0–139 months), 34 months for the patients with solitary SMs, and 48 months for those with multiple PTC SMs.

**PTC Group S.** The mean age of the 10 patients in the PTC Group S was 63 ± 14 years. There was no significant difference in the distribution of the bone non-SMs and solid organ metastases between the patients with solitary and multiple SMs. Three of the 10 patients had direct expansion of their tumors to the spine. Those three patients were significantly older than those in the PTC Group T (68 ± 7.4 years vs. 55 ± 15.3 years respectively; $p = 0.03$). Importantly, 67% of the patients with single-site SMs in the PTC Group S did not have any other distant metastases.

**PTC Group T.** In PTC Group T, 76% of the patients were found to have SMs at the time of TC diagnosis or to have developed SMs after TC diagnosis. Synchronous SMs were found in 20 (63%) patients, and metachronous SMs were evident in 12 (37%) patients within 34 months (0.5–144 months).
PTC Group S versus PTC Group T. There were no significant differences in the distribution of bone non-SMs and solid organ metastases between the patients of PTC Group S and PTC Group T.

Appearance of distant PTC metastases. Among the 36 patients available for analysis, 64% had initial distant bone metastases, 31% presented with bone and solid organ metastases at the same time, and 5% had initial solid organ metastases. This means that, altogether, solid organ metastases were diagnosed as first distant metastases in 36% of the patients, while 95% of the patients had bone metastases (Fig. 4).

Clinical presentation and treatments. A total of 28% of the patients presented with myelopathy (with or without radiculopathy), 9% with radiculopathy only, 25% of the patients had back pain as an initial symptom, and 38% of the patients were asymptomatic. Of the patients with PTC lesions, 43% were 131I avid, while 57% did not show an uptake of radioiodine. Information regarding treatment was available for 47 patients. Surgery was performed for 55% of the patients, nonsurgical treatments were provided for 28%, radiosurgery was used for 11% of the patients, and 6% did not receive any therapy.

FTC versus PTC

A comparative analysis of the patients with FTC and PTC revealed specific features (Table 2). Among the patients with FTC, females predominated (66%), while for PTC, males were in the majority (55%; \( p < 0.02 \)). SMs were a presenting symptom in FTC patients (41%) more often, while PTC SMs were more commonly identified after TC had been diagnosed (76%; \( p < 0.05 \)). Among the Group T patients, FTC presented more frequently with synchronous metastases (63%), while FTC was associated with metachronous metastases (64%).

| Table 2. COMPARISON OF DEMOGRAPHIC CHARACTERISTICS OF SPINAL METASTASES FROM FOLLICULAR AND PAPILLARY THYROID CANCER |
|-------------------------------------------------|-------------------------------------------------|---------------------------------|
| **Gender** | **Follicular thyroid cancer** | **Papillary thyroid carcinoma** | **p-Value** |
| Females | Males | \( p < 0.02 \) |
| Spinal metastases presented as an initial manifestation of thyroid cancer | Spinal metastases presented after thyroid cancer diagnosis | \( p < 0.05 \) |
| **Clinical manifestation** | **Type of metastases after thyroid cancer diagnosis** | **Mean time of developing SMs in Group T** | **p-Value** |
| Synchronous metastases | Metachronous metastases | 82.1 months | \( p < 0.01 \) |
| **Group S vs. Group T** | **Multisite vs. single-site SMs** | **Solid organ metastases were less common in Group S than in Group T (p<0.01)** | No correlation found |
| Multisite SMs were associated with bone nonsolid metastases, as compared to solitary SMs (p<0.01) | No correlation found | |
| **First distant metastases** | **Clinical presentation** | **Bone and solid organ metastases (31%)** | \( p < 0.05 \) |
| Bone (81%) | Back pain (25.5%) | |
| **Radioiodine uptake** | **Asymptomatic (38.3%)** | Negative (57.1%) | \( p < 0.01 \) |
| Positive (65.8%) | **Nonsurgical (27.7%)** | | \( p < 0.05 \) |
| **Treatment applied** | **Surgical (71.6%)** | | |

Discussion

The first description of TC SMs was provided by Max Runge in Virchow’s Archive in March 1876. He described a
Demographics of TC SMs

The relative incidence of PTC is higher (80%) than that of FTC (15%), but bone metastases are more frequent in patients with FTC compared to those with PTC at 7–28% and 1–7% respectively (64–68). As in other studies, we found SMs to be more common in FTC than PTC patients (64,69). Moreover, patients with FTC are usually older at the time of initial thyroid surgery (70). However, the mean age of the patients from our groups with SMs at FTC and PTC diagnosis were 57.8±14 years and 56.7±14.4 years respectively, without differences in histological type, indicating that SMs may be a later event in patients with FTC. This age difference is consistent with other studies and may be attributed to a more aggressive form of TC that is associated with metastatic disease and reduced survival (64,71–75).

Our male cohort constituted 41% of the patients. Other studies also showed a significant proportion of males with TC bone metastases (35–67%) compared to the male–female ratio seen in TC where females predominate. In contrast to those with FTC, among the patients with PTC, males predominated, which may indicate that sex is a risk factor for the development of FTC SMs. Furthermore, the males with PTC tended to be older than the females.

The most common mechanism for FTC metastatic spread is via a hematogenous route compared to the lymphatic spread of PTC (76). The propensity for axial skeleton SMs is thought to be secondary to blood flow distribution. Moreover, bone is a large repository for growth factors, which may assist in the propensity for bone seeding (68). We have demonstrated that the distribution of the FTC SMs matches the localization of the medullary segmental arteries (77,78).

Given that solitary SMs are found in roughly half the patients with SMs, perhaps a quarter of PTC and FTC patients with SMs can be considered for radical spinal surgery or radiosurgery to ensure the complete removal/destruction of metastatic tumor tissue with the intention of improving quality of life and potentially increasing survival. Certainly, patients with thyroid SMs are always at risk for additional bone or lung metastases in later years. Therefore, radical surgery or the radiosurgery of isolated SMs cannot be considered as curative treatments. However, utilizing these methods for patients with solitary thyroid SMs may potentially significantly prolong progression-free survival rates.

Moreover, those patients with TC who manifest with single-site SMs have a significantly lower probability of solid organ metastases compared to those who had SMs at the time of TC diagnosis or who developed TC during follow-up. The patients may initially present to a number of different medical specialties, such as neurology, orthopedics, neurosurgery, or general medicine (20). After an initial vertebral biopsy of the affected vertebra and confirmation of thyroid SMs, comprehensive imaging for the identification of other asymptomatic metastatic sites is important. For patients with SMs without bone non-SMs and solid organ metastases, radical treatment, that is, radiosurgery for localized vertebral lesions and total en-bloc spondylectomy for extended vertebral metastases, can be used. It seems that in the confirmed cases of thyroid SMs, when urgent surgery is required, the radical spinal surgery technique is preferable, since such patients have a relatively high chance of not having solid organ metastases.

Appearance of distant TC metastases

As previously shown, in terms of FTC, solid organ metastases were diagnosed as the first distant metastases in 19% of the patients in our study, with a subsequent increase to 48% during follow-up, while 95% of the patients had bone metastases. Even though all the patients had TC removal following the initial diagnosis of the disease, the number of solid organ metastases increased over time. In the case of PTC, 36% of the patients had solid organ metastases as the first distant metastases, and this number progressed to 42%, while 95% of the patients had bone metastases. It seems that little if no solid metastatic progression is seen. A large study on bone metastases—not only on spinal metastasis—is required to clarify metastatic progression.

Clinical presentation and treatments

Among all the patients with SMs, nearly 35% had an initial presentation of TC, whereas 65% were identified after TC diagnosis. According to our data, the FTC patients with SMs as an initial presentation had a significantly lower rate of solid organ involvement compared to Group T. The same was not evident for PTC patients. Accordingly, the patients with FTC had less advanced disease, and there was no age difference in comparison to the PTC patients. Bernier et al. also showed that patients who had signs of bone metastases as initial symptoms of TC had significantly higher survival rates (79).

In our study, SMs after TC diagnosis were almost equally divided between synchronous (46%) and metachronous metastases (54%). A similar distribution (50%/50%) was found by Zetting et al. for all bone metastases (1). To assess the distribution of SMs from FTC and PTC in this subgroup more precisely, we analyzed the synchronous and metachronous metastases in the patients in our study separately. The mean time for developing SMs in these patients was 35.3 months for PTC and 82.1 months for FTC. PTC often presented with synchronous metastases, while FTC mostly presented with metachronous metastases up to 372 months following the initial TC diagnosis. A heightened index of suspicion is a key element in the early evaluation and diagnosis of any patient with a history of TC.
Within our patient population, we identified a cohort of 10 women with FTC who had been operated on many years prior for seemingly benign thyroid lesions, and these patients later developed SMs. We can speculate that these patients had undiagnosed FTC microcarcinomas at the time of their original surgeries. These patients were considerably younger than the other FTC patients (36.4 ± 0.4 years vs. 56.7 ± 14.4 years respectively) and their metastases developed significantly later than those with other FTC metachronous metastases (221.7 ± 138 months vs. 101.5 ± 68.4 months respectively). With respect to the clinical presentation of thyroid SMs, the most commonly reported spinal symptoms were signs of direct neural structure compression, including myelopathy and radiculopathy (67% of the patients), and back pain (28%). The patients with FTC presented with SMs accompanied by symptoms of neural structure compression, while the PTC patients were more likely to present with back pain or to be asymptomatic.

In our study, only 57.8% of all TC lesions were 131I avid, while other studies showed the range to be 43–73% (74,79,80). In our analysis, 65.8% of the FTC and 42.9% of the PTC vertebral lesions were 131I avid. However, the effect and significance of radioidine therapy on SMs and its contribution is difficult to assess based on the existing literature. Our data may be biased because only lesions that we could clearly distinguish on scans were evaluated. Two-thirds (66.7%) of the patients in our study underwent surgery. Because FTC presented with symptoms of neural structure compression more often, surgery was used significantly more frequently for FTC than PTC patients. Radiosurgery, which has been shown to control tumor growth and palliate tumor-induced back pain, was used in 4.9% of the patients. External radiation was applied in 87% of the patients who received conservative treatment.

Conclusions

1. A significant proportion of TC patients with single-level SMs do not have any other distant metastases and may be considered for radical treatment.
2. Patients with SMs due to FTC who manifest TC have a better prognosis than those who develop SMs after TC diagnosis.
3. TC SMs may occur up to 372 months after the original TC diagnosis, which emphasizes the need for the long-term follow-up of patients with TC.
4. SMs originating from FTC and PTC appear to have distinct presentations, behaviors, and treatment modalities and should be categorized separately for treatment and follow-up planning.
5. The treatment of SMs requires a multidisciplinary approach that includes endocrine medical and surgical specialists, radiologists, and oncologists, in order to implement radical treatment methods (such as 131I total en bloc spondylectomy, and radiosurgery) if possible.

Acknowledgment

We are grateful to Valentin M. Dotsenko, MD, PhD, for his help in statistical analysis.

Author Disclosure Statement

No competing financial interests exist.

References

Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3184–3189.


Song HJ, Wu CG, Xue YL, Xu YH, Qiu ZL, Luo QY 2012 Percutaneous osteoplasty combined with radioiodine therapy


56. McNeeley MF Sabath A, Linnau KF 2012 Follicular thyroid carcinoma presenting as acute cord compression due to thoracic vertebral metastasis. Radiol Case Rep (Online) 7:687.


Address correspondence to:
Lisa M. Boyle, MD, FACS
Department of Surgery
MedStar Georgetown University Hospital
3800 Reservoir Road NW
Washington, DC 20007
E-mail: lisa.m.boyle@medstar.net